Duloxetine Capsule, Delayed Release
Product Images NDC 0615-8495

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 0615-8495). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structure (Duloxetine Dr Caps 8494 8495 8496 1)

Structure (Duloxetine Dr Caps 8494 8495 8496 1)
FDA Label Image

Figure 10 (Duloxetine Dr Caps 8494 8495 8496 10)

Figure 10 (Duloxetine Dr Caps 8494 8495 8496 10)
This text appears to be a table or chart showing the percentage of patients improved in a study comparing a placebo with duloxetine at 60/120 mg once daily. The table also includes a scale indicating percent improvement in pain from baseline.*
FDA Label Image

Principal Display Panel (20 MG)

Principal Display Panel (20 MG)
FDA Label Image

Principal Display Panel (30 MG)

Principal Display Panel (30 MG)
FDA Label Image

Principal Display Panel (60 MG)

Principal Display Panel (60 MG)
FDA Label Image

Figure 1 (Duloxetine Dr Caps 8494 8495 8496 2)

Figure 1 (Duloxetine Dr Caps 8494 8495 8496 2)
This text provides data on the proportion of patients with relapse in a study comparing the treatment of Placebo and Duloxetine. However, the information is incomplete and not clear enough to draw any specific conclusions.*
FDA Label Image

Figure 2 (Duloxetine Dr Caps 8494 8495 8496 3)

Figure 2 (Duloxetine Dr Caps 8494 8495 8496 3)
This text provides information about the proportion of patients experiencing relapse in a study comparing a placebo treatment to duloxetine. The data includes specific percentages corresponding to different time periods from randomization to relapse. Additionally, it mentions the use of the Kaplan-Meier estimator method for analysis.*
FDA Label Image

Figure 1 (Duloxetine Dr Caps 8494 8495 8496 4)

Figure 1 (Duloxetine Dr Caps 8494 8495 8496 4)
FDA Label Image

Figure 2 (Duloxetine Dr Caps 8494 8495 8496 5)

Figure 2 (Duloxetine Dr Caps 8494 8495 8496 5)
FDA Label Image

Fig 5 (Duloxetine Dr Caps 8494 8495 8496 6)

Fig 5 (Duloxetine Dr Caps 8494 8495 8496 6)
FDA Label Image

Fig 6 (Duloxetine Dr Caps 8494 8495 8496 7)

Fig 6 (Duloxetine Dr Caps 8494 8495 8496 7)
FDA Label Image

Figure 8 (Duloxetine Dr Caps 8494 8495 8496 8)

Figure 8 (Duloxetine Dr Caps 8494 8495 8496 8)
Not available*
FDA Label Image

Figure 9 (Duloxetine Dr Caps 8494 8495 8496 9)

Figure 9 (Duloxetine Dr Caps 8494 8495 8496 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.